TY - JOUR
T1 - Acute adverse events following gadolinium-based contrast agent administration
T2 - A single-center retrospective study of 281 945 injections
AU - McDonald, Jennifer S.
AU - Hunt, Christopher H.
AU - Kolbe, Amy B.
AU - Schmitz, John J.
AU - Hartman, Robert P.
AU - Maddox, Daniel E.
AU - Kallmes, David F.
AU - McDonald, Robert J.
N1 - Publisher Copyright:
© RSNA, 2019.
PY - 2019
Y1 - 2019
N2 - Background: Acute allergic-like and physiologic reactions occur following administration of gadolinium-based contrast agents (GBCAs) for MRI examinations. Because these reactions are uncommon, it is challenging to compare reaction rates between GBCAs and to determine risk factors. Purpose: To compare reaction rates between the four GBCAs gadodiamide, gadobutrol, gadobenate dimeglumine, and gadoterate meglumine, and to determine potential risk factors for reactions. Materials and Methods: This retrospective study identified all intravenous GBCA injections for MRI examinations performed at a single institution from June 1, 2009, to May 9, 2017. Reactions were identified by reviewing records from the MRI technologist, MRI nursing staff, radiologist, emergency department, and provider. Reactions were classified as allergic-like or physiologic and as mild, moderate, or severe by using American College of Radiology criteria. GBCA reaction rates and other potential risk factors were examined by using multivariable regression models with generalized estimating equations. Results: Analysis included a total of 158 100 patients (median age, 55 years [interquartile range, 40-67 years], 51% women) who received a total of 281 945 GBCA injections (140 645 gadodiamide, 94 109 gadobutrol, 39 138 gadobenate, and 8053 gadoterate). At multivariate analysis, gadobenate or gadobutrol had higher rates of allergic-like reactions compared with gadodiamide (gadobenate: Odds ratio [OR], 3.9 [95% confidence interval {CI}: 3.0, 5.1]; P , .001; gadobutrol: OR, 2.3 [95% CI: 1.8, 2.9]; P , .001) or gadoterate (gadobenate: OR, 4.8 [95% CI: 1.0, 23]; P = .049; gadobutrol: OR, 2.8 [95% CI: 0.6, 14]; P = .20). Physiologic reactions were more frequently observed with gadoterate (OR, 7.7 [95% CI: 2.3, 25; P = .001), gadobenate (OR, 1.8 [95% CI: 1.3, 2.5; P , .001), and gadobutrol (OR, 1.6 [95% CI: 1.3, 2.1; P , .001) administration compared with gadodiamide. Six severe allergic-like reactions (three gadobutrol, three gadobenate) occurred requiring hospitalization. Patient age (P values .025 to , .001), sex (P , .001), location (P = .006), and MRI type (P = .003 and P = .006) were associated with acute reactions. Conclusion: Gadobenate and gadobutrol are associated with higher rates of allergic-like reactions compared with gadodiamide or gadoterate, and gadoterate, gadobenate, and gadobutrol are associated with higher rates of physiologic reactions compared with gadodiamide. Patient sex, age, location, and MRI type correlate with acute reaction rates.
AB - Background: Acute allergic-like and physiologic reactions occur following administration of gadolinium-based contrast agents (GBCAs) for MRI examinations. Because these reactions are uncommon, it is challenging to compare reaction rates between GBCAs and to determine risk factors. Purpose: To compare reaction rates between the four GBCAs gadodiamide, gadobutrol, gadobenate dimeglumine, and gadoterate meglumine, and to determine potential risk factors for reactions. Materials and Methods: This retrospective study identified all intravenous GBCA injections for MRI examinations performed at a single institution from June 1, 2009, to May 9, 2017. Reactions were identified by reviewing records from the MRI technologist, MRI nursing staff, radiologist, emergency department, and provider. Reactions were classified as allergic-like or physiologic and as mild, moderate, or severe by using American College of Radiology criteria. GBCA reaction rates and other potential risk factors were examined by using multivariable regression models with generalized estimating equations. Results: Analysis included a total of 158 100 patients (median age, 55 years [interquartile range, 40-67 years], 51% women) who received a total of 281 945 GBCA injections (140 645 gadodiamide, 94 109 gadobutrol, 39 138 gadobenate, and 8053 gadoterate). At multivariate analysis, gadobenate or gadobutrol had higher rates of allergic-like reactions compared with gadodiamide (gadobenate: Odds ratio [OR], 3.9 [95% confidence interval {CI}: 3.0, 5.1]; P , .001; gadobutrol: OR, 2.3 [95% CI: 1.8, 2.9]; P , .001) or gadoterate (gadobenate: OR, 4.8 [95% CI: 1.0, 23]; P = .049; gadobutrol: OR, 2.8 [95% CI: 0.6, 14]; P = .20). Physiologic reactions were more frequently observed with gadoterate (OR, 7.7 [95% CI: 2.3, 25; P = .001), gadobenate (OR, 1.8 [95% CI: 1.3, 2.5; P , .001), and gadobutrol (OR, 1.6 [95% CI: 1.3, 2.1; P , .001) administration compared with gadodiamide. Six severe allergic-like reactions (three gadobutrol, three gadobenate) occurred requiring hospitalization. Patient age (P values .025 to , .001), sex (P , .001), location (P = .006), and MRI type (P = .003 and P = .006) were associated with acute reactions. Conclusion: Gadobenate and gadobutrol are associated with higher rates of allergic-like reactions compared with gadodiamide or gadoterate, and gadoterate, gadobenate, and gadobutrol are associated with higher rates of physiologic reactions compared with gadodiamide. Patient sex, age, location, and MRI type correlate with acute reaction rates.
UR - http://www.scopus.com/inward/record.url?scp=85071380749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071380749&partnerID=8YFLogxK
U2 - 10.1148/radiol.2019182834
DO - 10.1148/radiol.2019182834
M3 - Article
C2 - 31264948
AN - SCOPUS:85071380749
SN - 0033-8419
VL - 292
SP - 620
EP - 627
JO - Radiology
JF - Radiology
IS - 3
ER -